Quick Takeaways
- PHAT - Phathom Pharmaceuticals, Inc. has 19 insiders with reported activity on this page.
- Net insider value flow over the last year: +$190,168.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 19 Insiders of Phathom Pharmaceuticals, Inc.
- Symbol
- PHAT on Nasdaq
- Location
- Florham Park, NJ
What Changed
- Buy value: $216,973; sell value: $26,804.
- Net share flow: +66,726.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$190,168.
Buys
$216,973
Shares: 69,403
Insiders: 2
Sells
$26,804
Shares: 2,677
Insiders: 1
Net
+$190,168
Shares: +66,726
Insiders: 1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 524 | $0 | $7,079 | -$7,079 |
| 6-9 | 0 | 461 | $0 | $5,573 | -$5,573 |
| 9-12 | 69,403 | 1,692 | $216,973 | $14,152 | +$202,821 |
Phathom Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 10%+ Owner | $60,463,034 | Mixed | 24 Jan 2024 | ||
| TAKEDA PHARMACEUTICAL CO LTD | 10%+ Owner | $30,420,222 | Filing P/S | 24 Jan 2024 | ||
| James N. Topper | Director, 10%+ Owner | $19,639,309 | +$191,988 | +0.99% | Mixed | 03 Jun 2025 |
| David A. Socks | Director | $11,216,740 | Mixed | 23 May 2024 | ||
| Azmi Nabulsi | Chief Operating Officer | $10,029,637 | Mixed | 27 Feb 2025 | ||
| Steven L. Basta | President and CEO, Director | $4,785,898 | Mixed | 10 Feb 2026 | ||
| Sanjeev Narula | Chief Financial & Bus. Officer | $3,439,266 | Mixed | 02 Jan 2026 | ||
| Terrie Curran | President and Chief Executive, Director | $2,399,933 | Mixed | 27 Feb 2025 | ||
| Asit Parikh | Director | $1,602,130 | +$24,985 | +1.6% | Mixed | 10 Mar 2026 |
| Molly Henderson | CFO and CBO | $1,558,384 | Mixed | 07 Apr 2025 | ||
| Anne Marie Cook | Chief Legal Off. & Corp. Sec. | $1,136,621 | Mixed | 10 Feb 2026 | ||
| Robert Charles Breedlove | Principal Accounting Officer | $857,130 | -$26,804 | -3% | Mixed | 27 Feb 2026 |
| Frank Karbe | Director | $223,425 | Mixed | 03 Jun 2025 | ||
| Michael F. Cola | Director | $131,731 | Mixed | 03 Jun 2025 | ||
| Mark Stenhouse | Director | $99,300 | Mixed | 03 Jun 2025 | ||
| Heidi Fields | Director | $99,300 | Mixed | 03 Jun 2025 | ||
| Theodore R. Schroeder | Director | $95,577 | Mixed | 16 Apr 2025 | ||
| Anthony J. Guzzo | VP, Chief Accounting Officer | $71,787 | Mixed | 19 Jan 2022 | ||
| Tadataka Yamada | Director | Mixed | 21 May 2021 |
Top shareholders of Phathom Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
16%
|
12,466,489
|
$206,819,053 | — | 31 Dec 2025 | |
| Medicxi Ventures Management (Jersey) Ltd |
13F
3/4/5
|
Company · 10%+ Owner |
9.5%
|
7,464,572
|
$123,837,249 | — | 31 Dec 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
James N. Topper |
8.6%
|
5,985,327
|
$70,447,299 | $0 | 01 Nov 2025 | |
| Invesco Ltd. |
13F
|
Company |
5%
|
3,920,446
|
$65,040,200 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
4.6%
from 13D/G
|
3,555,548
|
$58,986,540 | — | 31 Dec 2025 | |
| Carlyle Group Inc. |
13F
13D/G
|
Company |
4.9%
from 13D/G
|
3,496,808
|
$57,977,077 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4%
|
3,177,211
|
$52,709,931 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
|
Company |
5.3%
|
4,178,411
|
$51,101,967 | +$25,636,905 | 06 Mar 2026 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
3%
|
2,352,020
|
$39,020,012 | — | 31 Dec 2025 | |
| NEA Management Company, LLC |
13F
|
Company |
2.5%
|
1,960,169
|
$32,519,204 | — | 31 Dec 2025 | |
| TAKEDA PHARMACEUTICAL CO LTD |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,755,583
|
$30,420,222 | — | 24 Jan 2024 | |
| 683 Capital Management, LLC |
13F
|
Company |
2.3%
|
1,785,000
|
$29,613,150 | — | 31 Dec 2025 | |
| Catalys Pacific, LLC |
13F
|
Company |
1.8%
|
1,429,014
|
$23,707,342 | — | 31 Dec 2025 | |
| WASATCH ADVISORS LP |
13F
|
Company |
1.7%
|
1,331,669
|
$22,092,389 | — | 31 Dec 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
1.7%
|
1,306,678
|
$21,678,000 | — | 31 Dec 2025 | |
| James N. Topper |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
5,950,827
mixed-class rows
|
$19,639,309 | +$191,988 | 03 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.5%
|
1,149,536
|
$19,070,802 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
1,073,434
|
$17,811,321 | — | 31 Dec 2025 | |
| Propel Bio Management, LLC |
13F
|
Company |
0.94%
|
740,918
|
$12,291,830 | — | 31 Dec 2025 | |
| Catalio Capital Management, LP |
13F
|
Company |
0.89%
|
698,996
|
$11,596,344 | — | 31 Dec 2025 | |
| David A. Socks |
3/4/5
|
Director |
—
mixed-class rows
|
1,248,756
mixed-class rows
|
$11,216,740 | — | 23 May 2024 | |
| Divisadero Street Capital Management, LP |
13F
|
Company |
0.84%
|
662,312
|
$10,987,756 | — | 31 Dec 2025 | |
| Azmi Nabulsi |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
1,406,436
mixed-class rows
|
$10,029,637 | — | 27 Feb 2025 | |
| MOORE CAPITAL MANAGEMENT, LP |
13F
|
Company |
0.76%
|
600,000
|
$9,954,000 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.7%
|
549,171
|
$9,110,747 | — | 31 Dec 2025 | |
| SummitTX Capital, L.P. |
13F
|
Company |
0.66%
|
517,820
|
$8,590,634 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.5%
|
397,910
|
$6,601,327 | — | 31 Dec 2025 | |
| NEXT CENTURY GROWTH INVESTORS LLC |
13F
|
Company |
0.5%
|
393,774
|
$6,532,710 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.5%
|
392,045
|
$6,504,026 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.49%
|
384,770
|
$6,383,334 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.45%
|
356,466
|
$5,913,771 | — | 31 Dec 2025 | |
| Simplify Asset Management Inc. |
13F
|
Company |
0.41%
|
321,935
|
$5,340,902 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.39%
|
311,315
|
$5,164,716 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.39%
|
304,383
|
$5,049,714 | — | 31 Dec 2025 | |
| StepStone Group LP |
13F
|
Company |
0.54%
|
422,085
|
$4,967,940 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.38%
|
296,684
|
$4,921,988 | — | 31 Dec 2025 | |
| Steven L. Basta |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
774,471
mixed-class rows
|
$4,785,898 | — | 10 Feb 2026 | |
| Brevan Howard Capital Management LP |
13F
|
Company |
0.35%
|
276,989
|
$4,595,247 | — | 31 Dec 2025 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.34%
|
267,962
|
$4,445,490 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.33%
|
261,068
|
$4,331,119 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.33%
|
258,996
|
$4,296,744 | — | 31 Dec 2025 | |
| Sanjeev Narula |
3/4/5
|
Chief Financial & Bus. Officer |
—
mixed-class rows
|
269,563
mixed-class rows
|
$3,439,266 | — | 02 Jan 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.26%
|
207,085
|
$3,435,540 | — | 31 Dec 2025 | |
| Avidity Partners Management LP |
13F
|
Company |
0.26%
|
206,076
|
$3,418,801 | — | 31 Dec 2025 | |
| Birchview Capital, LP |
13F
|
Company |
0.25%
|
195,000
|
$3,235,050 | — | 31 Dec 2025 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0.25%
|
200,823
|
$3,159,854 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.24%
|
187,291
|
$3,107,158 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.24%
|
185,744
|
$3,081,492 | — | 31 Dec 2025 | |
| CAXTON ASSOCIATES LLP |
13F
|
Company |
0.23%
|
181,968
|
$3,018,849 | — | 31 Dec 2025 | |
| HUSSMAN STRATEGIC ADVISORS, INC. |
13F
|
Company |
0.19%
|
147,000
|
$2,438,730 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Phathom Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Asit Parikh | PHAT | Common Stock | Gift | 49.7% | 40,000 | 120,500 | 10 Mar 2026 | by Trust | ||
| Asit Parikh | PHAT | Common Stock | Gift | -79.2% | -40,000 | 10,500 | 10 Mar 2026 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Tax liability | -2.19% | -1,378 | 61,480 | 27 Feb 2026 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Award | 33.6% | 15,790 | 62,858 | 27 Feb 2026 | Direct | ||
| Anne Marie Cook | PHAT | Common Stock | Tax liability | -1.7% | -1,535 | 88,660 | 10 Feb 2026 | Direct | ||
| Anne Marie Cook | PHAT | Common Stock | Award | 3.99% | 3,461 | 90,195 | 10 Feb 2026 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Tax liability | -1.65% | -6,277 | 373,315 | 10 Feb 2026 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Award | 3.37% | 12,362 | 379,592 | 10 Feb 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock | Gift | 80,500 | 80,500 | 23 Jan 2026 | by Trust | |||
| Asit Parikh | PHAT | Common Stock | Gift | -61.4% | -80,500 | 50,500 | 23 Jan 2026 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Tax liability | -1.62% | -776 | 47,068 | 21 Jan 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock | Options Exercise | 7.16% | 8,750 | 131,000 | 13 Jan 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock (Right to Buy) | Options Exercise | -100% | -8,750 | 0 | 13 Jan 2026 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Award | 220.6% | 251,034 | 364,820 | 02 Jan 2026 | Direct | ||
| Steven L. Basta | PHAT | Stock Option (Right to Buy) | Award | 226,156 | 221,156 | 02 Jan 2026 | Direct | |||
| Anne Marie Cook | PHAT | Common Stock | Award | 779.4% | 75,345 | 85,012 | 02 Jan 2026 | Direct | ||
| Anne Marie Cook | PHAT | Stock Option (Right to Buy) | Award | 67,878 | 67,878 | 02 Jan 2026 | Direct | |||
| Sanjeev Narula | PHAT | Common Stock | Award | 57.4% | 82,715 | 226,715 | 02 Jan 2026 | Direct | ||
| Sanjeev Narula | PHAT | Stock Option (Right to Buy) | Award | 42,848 | 42,848 | 02 Jan 2026 | Direct | |||
| Asit Parikh | PHAT | Common Stock | Options Exercise | 7.71% | 8,750 | 122,250 | 19 Dec 2025 | Direct | ||
| Asit Parikh | PHAT | Common Stock (Right to Buy) | Options Exercise | -50% | -8,750 | 8,750 | 19 Dec 2025 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Tax liability | -0.48% | -230 | 47,844 | 18 Dec 2025 | Direct | ||
| Anne Marie Cook | PHAT | Common Stock | Tax liability | -44.4% | -7,703 | 9,667 | 17 Dec 2025 | Direct | ||
| Anne Marie Cook | PHAT | Common Stock | Award | 17,370 | 17,370 | 17 Dec 2025 | Direct | |||
| Steven L. Basta | PHAT | Common Stock | Tax liability | -21.7% | -31,502 | 113,786 | 17 Dec 2025 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Award | 74.5% | 62,038 | 145,288 | 17 Dec 2025 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Tax liability | -36.8% | -48,375 | 83,250 | 28 Nov 2025 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Options Exercise | 216.2% | 90,000 | 131,625 | 28 Nov 2025 | Direct | ||
| Steven L. Basta | PHAT | Performance Shares | Options Exercise | -33.3% | -90,000 | 180,000 | 28 Nov 2025 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Sale | -1.09% | $7,079 | $13.51 | -524 | 47,407 | 03 Nov 2025 | Direct |
| Sanjeev Narula | PHAT | Common Stock | Award | 144,000 | 144,000 | 06 Oct 2025 | Direct | |||
| Steven L. Basta | PHAT | Common Stock | Tax liability | -53.8% | -48,375 | 41,625 | 25 Sep 2025 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Options Exercise | 90,000 | 90,000 | 25 Sep 2025 | Direct | |||
| Steven L. Basta | PHAT | Performance Shares | Options Exercise | -25% | -90,000 | 270,000 | 25 Sep 2025 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Sale | -0.95% | $5,573 | $12.09 | -461 | 47,931 | 05 Sep 2025 | Direct |
| Robert Charles Breedlove | PHAT | Common Stock | Sale | -3.38% | $14,152 | $8.36 | -1,692 | 48,392 | 16 Jul 2025 | Direct |
| Anne Marie Cook | PHAT | Stock Option (Right to Buy) | Award | 210,000 | 210,000 | 23 Jun 2025 | Direct | |||
| Frank Karbe | PHAT | Common Stock | Award | 18.4% | 10,500 | 67,500 | 03 Jun 2025 | Direct | ||
| Frank Karbe | PHAT | Stock Option (Right to Buy) | Award | 17,500 | 17,500 | 03 Jun 2025 | Direct | |||
| Michael F. Cola | PHAT | Common Stock | Award | 35.8% | 10,500 | 39,798 | 03 Jun 2025 | Direct | ||
| Michael F. Cola | PHAT | Stock Option (Right to Buy) | Award | 17,500 | 17,500 | 03 Jun 2025 | Direct | |||
| James N. Topper | PHAT | Common Stock | Award | 32.7% | 10,500 | 42,596 | 03 Jun 2025 | Direct | ||
| James N. Topper | PHAT | Stock Option (Right to Buy) | Award | 17,500 | 17,500 | 03 Jun 2025 | Direct | |||
| Heidi Fields | PHAT | Common Stock | Award | 53.8% | 10,500 | 30,000 | 03 Jun 2025 | Direct | ||
| Heidi Fields | PHAT | Stock Option (Right to Buy) | Award | 17,500 | 17,500 | 03 Jun 2025 | Direct | |||
| Mark Stenhouse | PHAT | Common Stock | Award | 53.8% | 10,500 | 30,000 | 03 Jun 2025 | Direct | ||
| Mark Stenhouse | PHAT | Stock Option (Right to Buy) | Award | 17,500 | 17,500 | 03 Jun 2025 | Direct | |||
| Asit Parikh | PHAT | Common Stock | Award | 10.2% | 10,500 | 113,500 | 03 Jun 2025 | Direct | ||
| Asit Parikh | PHAT | Stock Option (Right to Buy) | Award | 17,500 | 17,500 | 03 Jun 2025 | Direct | |||
| James N. Topper | PHAT | Common Stock | Purchase | 6.8% | $14,609 | $3.86 | 3,780 | 59,403 | 21 May 2025 | By Frazier Life Sciences X, L.P. |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.